Trials / Completed
CompletedNCT02182245
Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
A Phase I Open Label Dose Escalation Study of Oral Treatment With BIBF 1120 in Combination With Standard Treatment of Paclitaxel and Carboplatin in Patients With Advanced Gynaecological Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIBF 1120 | |
| DRUG | Paclitaxel | |
| DRUG | Carboplatin |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2007-01-01
- First posted
- 2014-07-08
- Last updated
- 2025-01-23
Source: ClinicalTrials.gov record NCT02182245. Inclusion in this directory is not an endorsement.